ABSCF Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EDT
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.12 - $1.45
Previous CloseN/A
Volume200.00
Average Volume (3M)0.00
Market Cap
$45.70M
Enterprise Value$55.46M
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Sep 25, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding73,251,990
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue47.24
Enterprise Value/Gross Profit77.03
Enterprise Value/Ebitda-45.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$1.38M
Bulls Say, Bears Say
Bulls Say
Debt ReductionA dramatic reduction in debt materially lowers interest and covenant pressure and improves financing optionality. Over a multi-month horizon this reduces near-term solvency risk, extends strategic runway for clinical programs, and makes non-dilutive partnership or licensing deals easier to negotiate.
Top-line Growth TrendConsistent revenue growth indicates strengthening commercial or development-stage traction and supports scaling if sustained. Over 2–6 months, improving top-line momentum can fund incremental R&D, validate market interest across indications, and improve negotiating leverage with partners or payers.
Diversified Pipeline FocusA single molecule being developed across multiple therapeutic areas spreads technical and commercial risk. Structurally, multiple indication pathways create several potential value inflection points and increase the chance of an approval or licensing outcome that can sustain long-term revenue generation.
Bears Say
Persistent Negative EquityNegative shareholder equity reflects cumulative losses and is a durable solvency red flag. Over 2–6 months it constrains access to capital, increases likelihood of dilutive financing or onerous terms, and limits the company's ability to absorb setbacks or fund late-stage clinical costs without partners.
Resumed Cash BurnReturn to sustained negative operating and free cash flow increases liquidity pressure and funding need. This persistent burn means management must secure financing or partnerships, often on dilutive terms, which can materially affect strategic flexibility and long-term program funding.
Fragile Capital StructureA small asset base limits borrowing capacity and collateral availability, making the firm vulnerable to shocks and less able to self-fund commercialization. Structurally this raises execution risk for multi-indication development unless sustained external funding or strategic partnerships are secured.
AB Science SA News
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was $1.12 and its highest was $1.45 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is $45.70M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 51 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.08.
How many shares outstanding does AB Science SA have?
AB Science SA has 73,251,990 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in ABSCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.